GB-2064 is under clinical development by Galecto and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II drugs for Myelofibrosis have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GB-2064’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GB-2064 overview

GB-2064 (PAT-1251) Is under development for the treatment of primary myelofibrosis and secondary myelofibrosis. The drug candidate is administered through oral route in the form of tablet. It acts by targeting LOXL2. It was also under development for the treatment of idiopathic pulmonary fibrosis, liver fibrosis and kidney fibrosis.

Galecto overview

Galecto (Galecto) is a drug development company that includes the development of galectin modulators for the treatment of cancer, fibrosis and inflammation. The company develops activators and inhibitors of galectins. Its pipeline products include GB0139 to treat

For a complete picture of GB-2064’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.